@article{ab25b0d8f6d643d085ccf2668987b7aa,
title = "High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902",
abstract = "Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m2 over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m2 on day 7 and 4.5mg/m2 on day 14 was not tolerated, but HiDAC followed by GO 9mg/m2 on day 7 was safe: 12/37 (32\%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.",
keywords = "Acute myeloid leukemia, Cytarabine, Gemtuzumab ozogamicin, Relapse",
author = "Stone, \{Richard M.\} and Barry Moser and Ben Sanford and Philip Schulman and Kolitz, \{Jonathan E.\} and Steven Allen and Wendy Stock and Ilene Galinsky and Ravi Vij and Guido Marcucci and David Hurd and Larson, \{Richard A.\}",
note = "Funding Information: The research for CALGB 19902 was supported, in part, by grants from the National Cancer Institute ( CA31946 ) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman) and to the CALGB Statistical Center (Stephen George, PhD, CA33601 ). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. The following institutions participated in this study: Christiana Care Health Services, Inc. CCOP, Wilmington, DE – Stephen Grubbs, MD, supported by CA45418; Hematology–Oncology Associates of Central New York CCOP, Syracuse, NY – Jeffrey Kirshner, MD, supported by CA45389; Kansas City Community Clinical Oncology Program CCOP, Kansas City, MO – Rakesh Gaur, MD; Dana-Farber Cancer Institute, Boston, MA – Harold J. Burstein, MD, supported by CA32291; North Shore Long Island Jewish Health System, New Hyde Park, NY – Daniel Budman, MD, supported by CA35279; Rhode Island Hospital, Providence, RI – William Sikov, MD, supported by CA08025; The Ohio State University Medical Center, Columbus, OH – Clara D. Bloomfield, MD, supported by CA77658; University of Chicago, Chicago, IL – Hedy L Kindler, MD, supported by CA41287; University of Illinois MBCCOP, Chicago, IL – David J. Peace, MD, supported by CA74811; University of Iowa, Iowa City, IA – Daniel A. Vaena, MD, supported by CA47642; University of Vermont, Burlington, VT – Hyman B. Muss, MD, supported by CA77406; Wake Forest University School of Medicine, Winston-Salem, NC – David D. Hurd, MD, supported by CA03927; Washington University School of Medicine, St. Louis, MO – Nancy Bartlett, MD, supported by CA77440; and Western Pennsylvania Cancer Institute, Pittsburgh, PA – Richard K. Shadduck, MD. ",
year = "2011",
month = mar,
doi = "10.1016/j.leukres.2010.07.017",
language = "English",
volume = "35",
pages = "329--333",
journal = "Leukemia Research",
issn = "0145-2126",
number = "3",
}